{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:21:49Z","timestamp":1794313309831,"version":"4.9.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["grant no. 952512"],"award-info":[{"award-number":["grant no. 952512"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study by the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) was designed to determine the incidence, risk factors, current management strategies, and outcomes of antibody-mediated rejection (ABMR) in pediatric kidney transplant recipients (pKTR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed an international, multicenter, longitudinal cohort study of data reported to the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry. Three hundred thirty-seven pKTR from 21 European centers were analyzed. Clinical outcomes, including kidney dysfunction, rejection, HLA donor-specific antibodies, BK polyomavirus-associated (BKPyV) nephropathy, and allograft loss, were assessed through 5\u00a0years post-transplant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cumulative incidence of de novo donor-specific class I HLA antibodies (HLA-DSA) post-transplant was 4.5% in year 1, 8.3% in year 3, and 13% in year 5; the corresponding data for de novo class II HLA-DSA were 10%, 22.5%, and 30.6%, respectively. For 5\u00a0years post-transplant, the cumulative incidence of acute ABMR was 10% and that of chronic active ABMR was 5.9%. HLA-DR mismatch and de novo HLA-DSA, especially double positivity for class I and class II HLA-DSA, were significant risk factors for ABMR, whereas cytomegalovirus (CMV) IgG negative recipient and CMV IgG negative donor were associated with a lower risk. BKPyV nephropathy was associated with the highest risk of graft dysfunction, followed by ABMR, T-cell mediated rejection, and older donor age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides an estimate of the incidence of de novo HLA-DSA and ABMR in pKTR and highlights the importance of BKPyV nephropathy as a strong risk factor for allograft dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-024-06487-2","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:02:26Z","timestamp":1726470146000},"page":"491-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients\u2014a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN)"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9939-4059","authenticated-orcid":false,"given":"Alexander","family":"Fichtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gauch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2521-8201","authenticated-orcid":false,"given":"Caner","family":"S\u00fcsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuong Hien","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Waldherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0409-5196","authenticated-orcid":false,"given":"Kai","family":"Krupka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-3083","authenticated-orcid":false,"given":"Isabella","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-9491","authenticated-orcid":false,"given":"Andrea","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-6176","authenticated-orcid":false,"given":"Matthias","family":"Zirngibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-5646","authenticated-orcid":false,"given":"Marcus","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-8656","authenticated-orcid":false,"given":"Jens","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"B\u00fcscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-0670","authenticated-orcid":false,"given":"Laszlo","family":"Berta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-7786","authenticated-orcid":false,"given":"Thomas","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-2602","authenticated-orcid":false,"given":"Atif","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-7389","authenticated-orcid":false,"given":"Krisztina","family":"Rusai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rezan","family":"Topaloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-3867","authenticated-orcid":false,"given":"Licia","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-9285","authenticated-orcid":false,"given":"Nikoleta","family":"Printza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4116-598X","authenticated-orcid":false,"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Melk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Patry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4131-2273","authenticated-orcid":false,"given":"Britta","family":"H\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-6910","authenticated-orcid":false,"given":"Burkhard","family":"T\u00f6nshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CERTAIN study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"6487_CR1","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJMra1802677","volume":"379","author":"A Loupy","year":"2018","unstructured":"Loupy A, Lefaucheur C (2018) Antibody-mediated rejection of solid-organ allografts. N Engl J Med 379:1150\u20131160","journal-title":"N Engl J Med"},{"key":"6487_CR2","doi-asserted-by":"publisher","first-page":"e14320","DOI":"10.1111\/ctr.14320","volume":"35","author":"A Hart","year":"2021","unstructured":"Hart A, Singh D, Brown SJ, Wang JH, Kasiske BL (2021) Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: a systematic review. Clin Transplant 35:e14320","journal-title":"Clin Transplant"},{"key":"6487_CR3","doi-asserted-by":"publisher","first-page":"5619402","DOI":"10.1155\/2017\/5619402","volume":"2017","author":"C S\u00fcsal","year":"2017","unstructured":"S\u00fcsal C, Fichtner A, T\u00f6nshoff B, Mehrabi A, Zeier M, Morath C (2017) Clinical relevance of HLA antibodies in kidney transplantation: recent data from the Heidelberg transplant center and the Collaborative Transplant Study. J Immunol Res 2017:5619402","journal-title":"J Immunol Res"},{"key":"6487_CR4","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/ajt.14169","volume":"17","author":"R Ettenger","year":"2017","unstructured":"Ettenger R, Chin H, Kesler K et al (2017) Relationship among viremia\/viral infection, alloimmunity, and nutritional parameters in the first year after pediatric kidney transplantation. Am J Transplant 17:1549\u20131562","journal-title":"Am J Transplant"},{"key":"6487_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2215\/CJN.16891020","volume":"17","author":"HE Fernandez","year":"2022","unstructured":"Fernandez HE, Foster BJ (2022) Long-term care of the pediatric kidney transplant recipient. Clin J Am Soc Nephrol 17:296\u2013304","journal-title":"Clin J Am Soc Nephrol"},{"key":"6487_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1314376","volume":"371","author":"VR Dharnidharka","year":"2014","unstructured":"Dharnidharka VR, Fiorina P, Harmon WE (2014) Kidney transplantation in children. N Engl J Med 371:549\u2013558","journal-title":"N Engl J Med"},{"key":"6487_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11560-015-0004-7","volume":"10","author":"B T\u00f6nshoff","year":"2015","unstructured":"T\u00f6nshoff B, Krupka K, K\u00f6ster L, Fichtner A, Pape L, H\u00f6cker B (2015) CERTAIN Registry. Der Nephrologe 10:480\u2013487","journal-title":"Der Nephrologe"},{"key":"6487_CR8","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.transproceed.2013.01.007","volume":"45","author":"L Plotnicki","year":"2013","unstructured":"Plotnicki L, Kohl CD, H\u00f6cker B et al (2013) The CERTAIN Registry: a novel, web-based registry and research platform for pediatric renal transplantation in Europe. Transplant Proc 45:1414\u20131417","journal-title":"Transplant Proc"},{"key":"6487_CR9","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1111\/ajt.14752","volume":"18","author":"AR Tambur","year":"2018","unstructured":"Tambur AR, Campbell P, Claas FH et al (2018) Sensitization in transplantation: assessment of risk (STAR) 2017 Working Group Meeting Report. Am J Transplant 18:1604\u20131614","journal-title":"Am J Transplant"},{"key":"6487_CR10","doi-asserted-by":"publisher","first-page":"e13528","DOI":"10.1111\/ctr.13528","volume":"33","author":"HH Hirsch","year":"2019","unstructured":"Hirsch HH, Randhawa PS (2019) AST infectious diseases community of practice. BK Polyomavirus in solid organ transplantation - guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 33:e13528","journal-title":"Clin Transplant"},{"key":"6487_CR11","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/ajt.15898","volume":"20","author":"A Loupy","year":"2020","unstructured":"Loupy A, Haas M, Roufosse C et al (2020) The Banff 2019 kidney meeting report (i): updates on and clarification of criteria for T cell\u2013 and antibody-mediated rejection. Am J Transplant 20:2318\u20132331","journal-title":"Am J Transplant"},{"key":"6487_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"6487_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/ki.2012.169","volume":"82","author":"GJ Schwartz","year":"2012","unstructured":"Schwartz GJ, Schneider MF, Maier PS et al (2012) Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 82:445\u2013453","journal-title":"Kidney Int"},{"key":"6487_CR14","doi-asserted-by":"publisher","first-page":"e13025","DOI":"10.1111\/ctr.13025","volume":"31","author":"JM Loucks-DeVos","year":"2017","unstructured":"Loucks-DeVos JM, Eagar TB, Osama Gaber A et al (2017) The detrimental impact of persistent vs an isolated occurrence of de novo donor-specific antibodies on intermediate-term renal transplant outcomes. Clin Transplant 31:e13025","journal-title":"Clin Transplant"},{"key":"6487_CR15","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1111\/j.1600-6143.2012.04251.x","volume":"12","author":"F Ginevri","year":"2012","unstructured":"Ginevri F, Nocera A, Comoli P et al (2012) Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 12:3355\u20133362","journal-title":"Am J Transplant"},{"key":"6487_CR16","doi-asserted-by":"publisher","first-page":"1747030","DOI":"10.1155\/2017\/1747030","volume":"2017","author":"M Cioni","year":"2017","unstructured":"Cioni M, Nocera A, Innocente A et al (2017) De novo donor-specific HLA antibodies developing early or late after transplant are associated with the same risk of graft damage and loss in nonsensitized kidney recipients. J Immunol Res 2017:1747030","journal-title":"J Immunol Res"},{"key":"6487_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00467-012-2101-4","volume":"27","author":"J Miettenen","year":"2012","unstructured":"Miettenen J, Per\u00e4saari J, Lauronen J et al (2012) Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr Nephrol 27:1011\u20131019","journal-title":"Pediatr Nephrol"},{"key":"6487_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1681\/ASN.2012070663","volume":"24","author":"A Chaudhuri","year":"2013","unstructured":"Chaudhuri A, Ozawa M, Everly MJ et al (2013) The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 24:655\u2013664","journal-title":"J Am Soc Nephrol"},{"key":"6487_CR19","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1111\/ajt.12859","volume":"14","author":"JJ Kim","year":"2014","unstructured":"Kim JJ, Balasubramanian R, Michaelides G et al (2014) The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients. Am J Transplant 14:2350\u20132358","journal-title":"Am J Transplant"},{"key":"6487_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ajt.2022.11.013","volume":"23","author":"C Lefaucheur","year":"2023","unstructured":"Lefaucheur C, Louis K, Morris AB et al (2023) Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: a sensitization in transplantation: assessment of risk consensus document. Am J Transplant 23:115\u2013132","journal-title":"Am J Transplant"},{"key":"6487_CR21","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/TP.0b013e318188af15","volume":"86","author":"G Offner","year":"2008","unstructured":"Offner G, T\u00f6nshoff B, H\u00f6cker B et al (2008) Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 86:1241\u20131248","journal-title":"Transplantation"},{"key":"6487_CR22","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/j.1600-6143.2006.01367.x","volume":"6","author":"R Grenda","year":"2006","unstructured":"Grenda R, Watson A, Vondrak K et al (2006) A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 6:1666\u20131672","journal-title":"Am J Transplant"},{"key":"6487_CR23","doi-asserted-by":"publisher","first-page":"E149","DOI":"10.1111\/petr.12129","volume":"17","author":"K Twombley","year":"2013","unstructured":"Twombley K, Thach L, Ribeiro A, Joseph C, Seikaly M (2013) Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience. Pediatr Transplantation 17:E149\u2013E155","journal-title":"Pediatr Transplantation"},{"key":"6487_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.6002\/ect.2012.0242","volume":"11","author":"K Gulleroglu","year":"2013","unstructured":"Gulleroglu K, Baskin E, Bayrakci US et al (2013) Antibody-mediated rejection and treatment in pediatric patients: one center\u2019s experience. Exp Clin Transplant 11:404\u2013407","journal-title":"Exp Clin Transplant"},{"key":"6487_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/petr.13079","volume":"21","author":"JA Steggerda","year":"2017","unstructured":"Steggerda JA, Kim IK, Haas M et al (2017) Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies. Pediatr Transplant 21:8","journal-title":"Pediatr Transplant"},{"key":"6487_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12026-021-09205-4","volume":"69","author":"AM Schuster","year":"2021","unstructured":"Schuster AM, Miesgang N, Steines L, Bach C, Banas B, Bergler B (2021) B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation. Immunol Res 69:487\u2013495","journal-title":"Immunol Res"},{"key":"6487_CR27","doi-asserted-by":"publisher","first-page":"10491","DOI":"10.3390\/ijms241310491","volume":"24","author":"R Alfaro","year":"2023","unstructured":"Alfaro R, Rodr\u00edguez-Aguilar L, Llorente S et al (2023) Early cytomegalovirus reactivation in renal recipients is associated with high levels of B cell maturation antigen transcript expression prior to transplantation. Int J Mol Sci 24:10491","journal-title":"Int J Mol Sci"},{"key":"6487_CR28","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1097\/TXD.0000000000000750","volume":"3","author":"CM Michelo","year":"2017","unstructured":"Michelo CM, van Cranenbroek B, Touw P, Claas FHJ, van der Meer A, Joosten I (2017) Human cytomegalovirus infection increases both antibody- and non\u2013antibody-dependent cellular reactivity by natural killer cells. Transplantation Direct 3:e335","journal-title":"Transplantation Direct"},{"key":"6487_CR29","first-page":"3","volume":"6","author":"L Couzi","year":"2017","unstructured":"Couzi L, Pitard V, Moreau J, Merville P, D\u00e9chanet-Merville J (2017) Direct and indirect effects of cytomegalovirus-induced \u03b3\u03b4 T cells after kidney transplantation. Front Immunol 6:3","journal-title":"Front Immunol"},{"key":"6487_CR30","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2009111188","volume":"21","author":"JM Smith","year":"2010","unstructured":"Smith JM, Corey L, Bittner R, Finn LS, Healey PJ, Davis CL, McDonald RA (2010) Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21:1579\u20131586","journal-title":"J Am Soc Nephrol"},{"key":"6487_CR31","first-page":"14","volume":"15","author":"A Saldan","year":"2023","unstructured":"Saldan A, Mengoli C, Sgarabotto D et al (2023) Human cytomegalovirus and Epstein-Barr virus infections occurring early after transplantation are risk factors for antibody-mediated rejection in heart transplant recipients. Front Immunol 15:14","journal-title":"Front Immunol"},{"key":"6487_CR32","doi-asserted-by":"publisher","first-page":"e13569","DOI":"10.1111\/tid.13569","volume":"23","author":"D Boutolleau","year":"2021","unstructured":"Boutolleau D, Coutance G, D\u00e9sir\u00e9 E, Bougl\u00e9 A, Br\u00e9chot N, Leprince P, Varnous S (2021) Association between cytomegalovirus infection and allograft rejection in a large contemporary cohort of heart transplant recipients. Transpl Infect Dis 23:e13569","journal-title":"Transpl Infect Dis"},{"key":"6487_CR33","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1681\/ASN.2020071106","volume":"32","author":"K Doberer","year":"2021","unstructured":"Doberer K, Duerr M, Halloran PF et al (2021) A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32:708\u2013722","journal-title":"J Am Soc Nephrol"},{"key":"6487_CR34","doi-asserted-by":"publisher","first-page":"e14734","DOI":"10.1111\/ctr.14734","volume":"36","author":"M Pearl","year":"2022","unstructured":"Pearl M, Weng PL, Chen L et al (2022) Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. Clin Transplant 36:e14734","journal-title":"Clin Transplant"},{"key":"6487_CR35","unstructured":"National Library of Medicine. National Center for Biotechnology Information (2022) BIVV020 in prevention and treatment of Antibody-mediated Rejection (AMR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05156710. Accessed 25 February 2022"},{"key":"6487_CR36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/TP.0000000000003095","volume":"104","author":"CA Schinstock","year":"2020","unstructured":"Schinstock CA, Mannon RB, Budde K et al (2020) Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group. Transplantation 104:911\u2013922","journal-title":"Transplantation"},{"key":"6487_CR37","doi-asserted-by":"publisher","first-page":"11381","DOI":"10.3389\/ti.2023.11381","volume":"36","author":"LPE Rostaing","year":"2023","unstructured":"Rostaing LPE, B\u00f6hmig GA, Gibbons B, Taqi MM (2023) Post-transplant surveillance and management of chronic active antibody-mediated rejection in renal transplant patients in Europe. Transpl Int 36:11381","journal-title":"Transpl Int"},{"key":"6487_CR38","first-page":"23","volume":"35","author":"B H\u00f6cker","year":"2022","unstructured":"H\u00f6cker B, Schmidt J, S\u00fcsal C et al (2022) Risk of cellular and\/or antibody-mediated transplant rejection in pediatric kidney transplant recipients with BK polyomavirus DNAemia \u2013 a multicenter CERTAIN analysis. Transplant Int 35:23","journal-title":"Transplant Int"},{"key":"6487_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMoa035717","volume":"352","author":"D Dragun","year":"2005","unstructured":"Dragun D, M\u00fcller DN, Br\u00e4sen JH et al (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352:558\u2013569","journal-title":"N Engl J Med"},{"key":"6487_CR40","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/ndt\/gfy008","volume":"33","author":"A Fichtner","year":"2018","unstructured":"Fichtner A, S\u00fcsal C, Schr\u00f6der C et al (2018) Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients. Nephrol Dial Transplant 33:1065\u20131072","journal-title":"Nephrol Dial Transplant"},{"key":"6487_CR41","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00467-021-04969-1","volume":"36","author":"A Fichtner","year":"2021","unstructured":"Fichtner A, S\u00fcsal C, H\u00f6cker B et al (2021) Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients. Pediatr Nephrol 36:2473\u20132484","journal-title":"Pediatr Nephrol"},{"key":"6487_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.kint.2021.04.044","volume":"100","author":"C Lefaucheur","year":"2021","unstructured":"Lefaucheur C, Louis K, Philippe A, Loupy A, Coates PT (2021) The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond. Kidney Int 100:787\u2013798","journal-title":"Kidney Int"},{"key":"6487_CR43","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ajt.2023.07.004","volume":"23","author":"J Hogan","year":"2023","unstructured":"Hogan J, Divard G, Aubert O et al (2023) Validation of a prediction system for risk of kidney allograft failure in pediatric kidney transplant recipients: an international observational study. Am J Transplant 23:1561\u20131569","journal-title":"Am J Transplant"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06487-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06487-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06487-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T14:02:22Z","timestamp":1734962542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06487-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6487"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06487-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4016549\/v1","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"5 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexander Fichtner has received travel grants from Astellas and Novartis. Licia Peruzzi has received consulting fees from Alexion. Lutz T. Weber has received a research grant from Chiesi. Britta H\u00f6cker has received consulting fees from GlaxoSmithKline. Burkhard T\u00f6nshoff has received research grants from Novartis, Astellas, and Chiesi, and consulting fees from Bristol-Myers Squibb, CSL Behring Biotherapies for Life, Vifor, and Chiesi. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}